文献速递神经肿瘤

[11C]甲硫氨酸PET在初诊未治胶质瘤中的诊断效能:基于WHO 2016分类

Diagnostic Performance of [11C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification.
PubMed 文献 · World Neurosurg · 2021-01-11

该回顾性研究纳入68例初诊未治胶质瘤患者,术前接受[11C]甲硫氨酸PET检查。结果显示弥漫性星形细胞瘤的L/N比值显著低于间变性星形细胞瘤、胶质母细胞瘤和少突胶质细胞瘤;IDH突变型胶质瘤L/N比值显著低于IDH野生型(中位1.75 vs 2.61,P=0.00162),L/N比值2.05区分两者敏感性69.2%、特异性76.2%。仅凭[11C]甲硫氨酸PET难以区分WHO 2016胶质瘤亚型,但可能有助于无创预测IDH突变状态。

要点

  • [11C]甲硫氨酸PET的L/N比值在IDH突变型胶质瘤中显著低于IDH野生型。
  • L/N比值2.05区分IDH突变与野生型的敏感性69.2%、特异性76.2%。
  • 仅凭该PET难以区分WHO 2016胶质瘤亚型,病理诊断是L/N比值的唯一影响因素。

核心结论

  • 仅凭[11C]甲硫氨酸PET区分基于WHO 2016分类的胶质瘤亚型似乎困难,但可能有助于术前无创预测IDH突变状态。

研究设计与样本

  • 回顾性研究,纳入2011年7月至2018年3月在大阪市立大学医院接受手术切除且术前行[11C]甲硫氨酸PET检查的68例初诊未治胶质瘤患者,依据病历资料回顾临床与影像学资料。

主要发现

  • 弥漫性星形细胞瘤平均L/N比值显著低于间变性星形细胞瘤(P=0.00155)、胶质母细胞瘤(P<0.001)和少突胶质细胞瘤(P=0.0157)。
  • IDH突变型胶质瘤平均L/N比值显著低于IDH野生型(中位1.75 vs 2.61;P=0.00162)。
  • TERT启动子突变型胶质瘤平均L/N比值显著高于TERT启动子野生型(P=0.0147)。
  • 多因素回归分析显示病理诊断是L/N比值的唯一影响因素。

关键数值与推荐

  • L/N比值2.05为区分IDH突变型与IDH野生型胶质瘤的最佳阈值,敏感性69.2%、特异性76.2%。

临床怎么用

  • 对初诊未治胶质瘤患者,术前[11C]甲硫氨酸PET的L/N比值可作为无创预测IDH突变状态的参考,但不能替代病理诊断进行WHO 2016亚型区分。

局限性

  • 为单中心回顾性研究,样本量68例,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship between uptake of amino acid tracer with positron emission tomography (PET) and glioma subtypes/gene status is still unclear. OBJECTIVE: To assess the relationship between uptake of [11C]methionine using PET and pathology, IDH (isocitrate dehydrogenase) mutation, 1p/19q codeletion, and TERT (telomerase reverse transcriptase) promoter status in gliomas. METHODS: The participants were 68 patients with newly diagnosed and untreated glioma who underwent surgical excision and preoperative [11C]methionine PET examination at Osaka City University Hospital between July 2011 and March 2018. Clinical and imaging studies were reviewed retrospectively based on the medical records at our institution. RESULTS: The mean lesion/contralateral normal brain tissue (L/N) ratio of diffuse astrocytomas was significantly lower than that of anaplastic astrocytomas (P = 0.00155), glioblastoma (P < 0.001), and oligodendrogliomas (P = 0.0157). The mean L/N ratio of IDH mutant gliomas was significantly lower than that of IDH wild-type gliomas (median 1.75 vs. 2.61; P = 0.00162). A mean L/N ratio of 2.05 provided the best sensitivity and specificity for distinguishing between IDH mutant and IDH wild-type gliomas (69.2% and 76.2%, respectively). The mean L/N ratio of TERT promoter mutant gliomas was significantly higher than that of TERT promoter wild-type gliomas (P = 0.0147). Multiple regression analysis showed that pathologic diagnosis was the only influential factor on L/N ratio. CONCLUSIONS: Distinguishing glioma subtypes based on the revised 2016 World Health Organization classification of the central nervous system tumors on the basis of [11C]methionine PET alone seems to be difficult. However, [11C]methionine PET might be useful for predicting the IDH mutation status in newly diagnosed and untreated gliomas noninvasively before tumor resection.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Nakajo K, Uda T, Kawashima T, et al. Diagnostic Performance of [11C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification. World Neurosurg. 2021. PMID: 33444827. doi:10.1016/j.wneu.2021.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。